Business Segments — income (loss)
Vertex Pharmaceuticals Business Segments — income (loss) decreased by 13.4% to $1.03B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 59.6%, from $646.3M to $1.03B. Over 2 years (FY 2022 to FY 2025), Business Segments — income (loss) shows an upward trend with a 9.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates improved operational efficiency or stronger product demand, while a decrease may signal rising R&D costs, commercialization investments, or competitive pressure on drug pricing.
Detailed definition
This metric represents the operating profitability of the core pharmaceutical business segment after accounting for all...
Peer comparison
Comparable to operating income or segment profit reported by other large-cap biotechnology and pharmaceutical companies, though variations exist based on how firms allocate R&D and corporate overhead.
vrtx_segment_pharmaceuticals_income_lossHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $830.5M | $830.5M | $830.5M | $830.5M | $904.9M | $904.9M | $904.9M | $904.9M | $1.1B | -$3.59B | $1.05B | $646.3M | $1.03B | $1.08B | $1.19B | $1.03B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +9.0% | +0.0% | +0.0% | +0.0% | +21.5% | -426.8% | +129.1% | -38.2% | +59.8% | +4.8% | +10.0% | -13.4% |
| YoY Change | — | — | — | — | +9.0% | +9.0% | +9.0% | +9.0% | +21.5% | -497.1% | +15.5% | -41.2% | +128.7% | +3.6% | — | +59.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — income (loss)?
- Vertex Pharmaceuticals (VRTX) reported business segments — income (loss) of $1.03B in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — income (loss) changed year-over-year?
- Vertex Pharmaceuticals's business segments — income (loss) increased by 59.6% year-over-year, from $646.3M to $1.03B.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — income (loss)?
- Over 2 years (2022 to 2025), Vertex Pharmaceuticals's business segments — income (loss) has grown at a 9.1% compound annual growth rate (CAGR), from $3.32B to $3.95B.
- What does business segments — income (loss) mean?
- The net profit or loss generated specifically by the pharmaceutical business segment after all related operating expenses.